Does knockout of Adamts7 reduce atherosclerosis in mice?
In vivo experimental validation demonstrates that Adamts7 is proatherogenic, suggesting that its pharmacological inhibition could be a novel therapeutic target for coronary artery disease.
These data represent the first in vivo experimental validation of the association of Adamts7 with atherogenesis, likely through modulation of vascular cell migration and matrix in atherosclerotic lesions. These results demonstrate that Adamts7 is proatherogenic, lending directionality to the original genetic association and supporting the concept that pharmacological inhibition of ADAMTS7 should be atheroprotective in humans, making it an attractive target for novel therapeutic interventions.
Bauer et al. (Thu,) studied this question.